Max Kates
YOU?
Author Swipe
View article: Patient-reported outcomes following UGN-102 treatment in low-grade intermediate-risk non-muscle invasive bladder cancer: An analysis of three clinical trials
Patient-reported outcomes following UGN-102 treatment in low-grade intermediate-risk non-muscle invasive bladder cancer: An analysis of three clinical trials Open
In these analyses, patients with LG-IR-NMIBC receiving UGN-102 did not report worsening QoL, functioning, or symptom burden, supporting its use as a nonsurgical treatment for LG-IR-NMIBC.
View article: Sparing urethra in women at the time of cystectomy: retrospective comparison of cystectomies with and without urethrectomy
Sparing urethra in women at the time of cystectomy: retrospective comparison of cystectomies with and without urethrectomy Open
Urethra-sparing cystectomy in women may be oncologically safe when no urethral involvement is present and should be considered to preserve sexual function.
View article: Sarcomatoid areas of urothelial carcinoma are enriched for <scp>CD163</scp>‐positive antigen‐presenting cells
Sarcomatoid areas of urothelial carcinoma are enriched for <span>CD163</span>‐positive antigen‐presenting cells Open
Sarcomatoid urothelial carcinoma (SUC) is a rare histologic subtype with poor prognosis. While there is known intra‐tumoral heterogeneity between individual SUC tumors, the relationship between sarcomatoid and conventional urothelial carci…
View article: Molecular Characterization of N-Methyl-N-Nitrosourea (Mnu)-Induced Urothelial Carcinoma in a Rat Model Reveals Hallmarks of Both Luminal and Basal Subtypes
Molecular Characterization of N-Methyl-N-Nitrosourea (Mnu)-Induced Urothelial Carcinoma in a Rat Model Reveals Hallmarks of Both Luminal and Basal Subtypes Open
View article: Detection of High-Grade Bladder Cancer in Urine Samples Using in Situ Hybridization of Long Non-Coding Rna Uca1
Detection of High-Grade Bladder Cancer in Urine Samples Using in Situ Hybridization of Long Non-Coding Rna Uca1 Open
View article: ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) randomised controlled trial protocol
ERAS for Ambulatory TURBT: Enhancing Bladder Cancer Care (EMBRACE) randomised controlled trial protocol Open
Introduction Transurethral resection of bladder tumour (TURBT) is one of the more common procedures performed by urologists. It is often described as an ‘incision-free’ and ‘well-tolerated’ operation. However, many patients experience dist…
View article: Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis Open
BACKGROUND: Sarcomatoid urothelial cancer of the bladder (SBC) is a rare, but aggressive histological subtype for which novel treatments are needed. OBJECTIVE: We evaluated the clinical activity and safety of neoadjuvant cisplatin plus gem…
View article: Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712
Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712 Open
View article: Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry
Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry Open
The use of blue light cystoscopy (BLC) has been shown to improve bladder tumor detection. However, data demonstrating the efficacy of BLC across different races are limited. Herein, we aim to evaluate heterogeneity in the characteristics o…
View article: Tumour tissue‐derived small extracellular vesicles reflect molecular subtypes of bladder cancer
Tumour tissue‐derived small extracellular vesicles reflect molecular subtypes of bladder cancer Open
mRNA‐based molecular subtypes have implications for bladder cancer prognosis and clinical benefit from certain therapies. Whether small extracellular vesicles (sEVs) can reflect bladder cancer molecular subtypes is unknown. We performed wh…
View article: Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist
Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist Open
Despite the introduction of several new agents for the treatment of bladder cancer (BC), intravesical BCG remains a first line agent for the management of non-muscle invasive bladder cancer. In this study we evaluated the antitumor efficac…
View article: Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer
Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer Open
Background Bladder cancer poses a significant public health burden, with high recurrence and progression rates in patients with non-muscle-invasive bladder cancer (NMIBC). Current treatment options include bladder-sparing therapies (BST) a…
View article: Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer Open
BACKGROUND: Despite recent drug development for non-muscle invasive bladder cancer (NMIBC), few therapies have been approved by the US Food and Drug Administration (FDA), and there remains an unmet clinical need. Bacillus Calmette-Guerin (…
View article: Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE) Open
View article: Cover Image
Cover Image Open
The cover image is based on the Original Article Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small-cell carcinoma of the bladder by Vamsi Parimi …
View article: Supplementary Tables from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Supplementary Tables from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer Open
Supplementary Table 1: Relative Gene Expression of outlier "immune response" genes after BCG vs no treatment in sorted CD8+ cells from bladder cancer. Supplementary Table 2: Relative Gene Expression of outlier "immune response" genes after…
View article: Supplementary Figure 2 from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Supplementary Figure 2 from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer Open
(A) Rats 8 weeks post MNU were treated intravesically with MMC, MMC+BCG, and Cisplatin for 6 weeks (n=5 for each group). Bladders were harvested at week 16 and then digested into single cell suspensions and T cell populations analyzed with…
View article: Supplementary Figure 3 from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Supplementary Figure 3 from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer Open
5 BCG treated rats, 5 untreated rats, and 20 controls rat were sacrificed and bladders were processed in single cell suspensions. CD4 and CD8 T cells were isolated for each sample and RNA was extracted. A gene expression analysis was subse…
View article: Supplementary Figure Legends from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Supplementary Figure Legends from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer Open
Supplementary Figure Legends
View article: Supplementary Tables from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Supplementary Tables from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer Open
Supplementary Table 1: Relative Gene Expression of outlier "immune response" genes after BCG vs no treatment in sorted CD8+ cells from bladder cancer. Supplementary Table 2: Relative Gene Expression of outlier "immune response" genes after…
View article: Supplementary Figure 2 from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Supplementary Figure 2 from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer Open
(A) Rats 8 weeks post MNU were treated intravesically with MMC, MMC+BCG, and Cisplatin for 6 weeks (n=5 for each group). Bladders were harvested at week 16 and then digested into single cell suspensions and T cell populations analyzed with…
View article: Data from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Data from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer Open
Intravesical bacillus Calmette–Guérin (BCG) immunotherapy is the standard of care in treating non–muscle-invasive bladder cancer, yet its mechanism of action remains elusive. Both innate and adaptive immune responses have been implicated i…
View article: Data from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Data from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer Open
Intravesical bacillus Calmette–Guérin (BCG) immunotherapy is the standard of care in treating non–muscle-invasive bladder cancer, yet its mechanism of action remains elusive. Both innate and adaptive immune responses have been implicated i…
View article: Supplementary Figure 3 from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Supplementary Figure 3 from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer Open
5 BCG treated rats, 5 untreated rats, and 20 controls rat were sacrificed and bladders were processed in single cell suspensions. CD4 and CD8 T cells were isolated for each sample and RNA was extracted. A gene expression analysis was subse…
View article: Supplementary Figure Legends from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Supplementary Figure Legends from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer Open
Supplementary Figure Legends
View article: Supplementary Figure 1 from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Supplementary Figure 1 from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer Open
Flow cytometry gating strategy is outlined. After digestion of tumor infiltrated bladders, samples yielded 1-2 million cells per bladder. A) Live T lymphocyte subpopulations were then gated from spleen tissue, and B) bladder T cells of int…
View article: Supplementary Figure 1 from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer
Supplementary Figure 1 from Intravesical BCG Induces CD4<sup>+</sup> T-Cell Expansion in an Immune Competent Model of Bladder Cancer Open
Flow cytometry gating strategy is outlined. After digestion of tumor infiltrated bladders, samples yielded 1-2 million cells per bladder. A) Live T lymphocyte subpopulations were then gated from spleen tissue, and B) bladder T cells of int…
View article: Supplementary Data from Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials
Supplementary Data from Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials Open
Supplementary Figure 1
View article: Supplementary Data from Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials
Supplementary Data from Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials Open
Supplementary Figure 2
View article: Supplementary Tables from Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer
Supplementary Tables from Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non–Muscle-Invasive Bladder Cancer Open
Supplementary Table 1: Nanoparticle physicochemical characteristics. Table S2: IC50 values of various formulations against various bladder cancer cell lines.